ECSP993125A - PIPERIDINE DERIVATIVES - Google Patents
PIPERIDINE DERIVATIVESInfo
- Publication number
- ECSP993125A ECSP993125A ECSP993125A ECSP993125A EC SP993125 A ECSP993125 A EC SP993125A EC SP993125 A ECSP993125 A EC SP993125A EC SP993125 A ECSP993125 A EC SP993125A
- Authority
- EC
- Ecuador
- Prior art keywords
- lower alkyl
- disorders
- lower alkoxy
- cycloalkyl
- disease
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 206010012289 Dementia Diseases 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000027796 Blood pressure disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000013200 Stress disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
El presente invento se refirere a compuestos de la fórmula general (gráfico), en donde R1 es tetrahidronaftilo; o -(CH2)nC6H5-R4 es H, alquilo inferior o alcoxilo inferior; o cicloalquilo de C5-C12, opcionalmente sustituido por alquilo inferior; R2 es H, OH, alcoxilo inferior, alqueniloxilo inferior o alquilo inferior; R3 es cicloalquilo de C5-C7 o fenilo, opcionalmente sustituido por OH, halógeno, alcoxilo inferior, alqueniloxilo inferior, alquilo inferior u -O-(CH2)n-C6H5 en donde n es 0-3; y a sus sales de adición de ácido farmacéuticamente aceptables. Los compuestos de la fórmula general I son apropiados para el tratamiento de deficits de memoria y atención, transtornos psiquiátricos, neurológicos y fisiológicos, tal como ansiedad y trastornos de estres, depresión, pérdida de memoria debido a enfermedad de Alzheimer u otras demencias tales como demencia vascular y complejo por demencia por SIDA, enfermedad de Parkinson, epilepsia y convulsiones, condiciones de dolor agudo y/ocrónico, sintomas de abstinencia de drogas adictas y reducción de su abuso/deseo, control de equilibrio de agua, excresión de Na+ y trastornos de presión arterial y trastornos metabólicos tal como obesidad.The present invention relates to compounds of the general formula (graph), wherein R1 is tetrahydronaphthyl; or - (CH2) nC6H5-R4 is H, lower alkyl or lower alkoxy; or C5-C12 cycloalkyl, optionally substituted by lower alkyl; R2 is H, OH, lower alkoxy, lower alkenyloxy or lower alkyl; R3 is C5-C7 cycloalkyl or phenyl, optionally substituted by OH, halogen, lower alkoxy, lower alkenyloxy, lower alkyl or -O- (CH2) n-C6H5 where n is 0-3; and its pharmaceutically acceptable acid addition salts. The compounds of the general formula I are suitable for the treatment of memory and attention deficits, psychiatric, neurological and physiological disorders, such as anxiety and stress disorders, depression, memory loss due to Alzheimer's disease or other dementias such as dementia vascular and complex due to AIDS dementia, Parkinson's disease, epilepsy and seizures, acute and / or chronic pain conditions, addicted drug withdrawal symptoms and reduced abuse / desire, control of water balance, Na + excision and disorders of blood pressure and metabolic disorders such as obesity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP993125 ECSP993125A (en) | 1999-09-07 | 1999-09-07 | PIPERIDINE DERIVATIVES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP993125 ECSP993125A (en) | 1999-09-07 | 1999-09-07 | PIPERIDINE DERIVATIVES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP993125A true ECSP993125A (en) | 2000-05-08 |
Family
ID=42044113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP993125 ECSP993125A (en) | 1999-09-07 | 1999-09-07 | PIPERIDINE DERIVATIVES |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP993125A (en) |
-
1999
- 1999-09-07 EC ECSP993125 patent/ECSP993125A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2960717T3 (en) | [9,10-Dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods related to it | |
| AR016431A1 (en) | DERIVATIVES OF PIPERIDINE, A PROCESS FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THEM AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| JP6434425B2 (en) | S1P regulator | |
| SE0202134D0 (en) | Therapeutic agents | |
| SE0104334D0 (en) | Therapeutic agents | |
| TW200740760A (en) | Malonamide derivatives | |
| TW200738645A (en) | Use of 4-imidazole derivatives for CNS disorders | |
| JP2002508362A (en) | 1-Substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogs), their preparation and their use in the treatment of neurological diseases | |
| KR19990082349A (en) | As a pharmaceutical preparation, a novel cyclic amino acid | |
| EA018412B1 (en) | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators | |
| WO2008061796A3 (en) | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | |
| AR022083A1 (en) | PIPERIDINE DERIVATIVES | |
| CA2217197A1 (en) | Novel heterocyclic compounds | |
| WO2022169868A1 (en) | Compounds for treating spinocerebellar ataxia type 3 | |
| BR9805297A (en) | Derivatives of 1,3,8-triazaspiro (4,5) decan-4on. | |
| JP2014098006A (en) | Dibenzothiazepine derivatives and uses thereof | |
| MA32978B1 (en) | Derivatives 2- pyridine -2-yl-pyrazole -3 (2h) en, prepared and applied in treatment | |
| AR051802A1 (en) | MCHR1 ANTAGONIST HETEROCICLES | |
| TW200626568A (en) | Malonamide derivatives | |
| US6420566B2 (en) | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | |
| ECSP993125A (en) | PIPERIDINE DERIVATIVES | |
| EP2512241A1 (en) | Compounds for the treatment of neurologic disorders | |
| AU630135B2 (en) | Novel benzopyranylpyrrolinone derivatives | |
| WO2022169866A1 (en) | Methods for treating spinocerebellar ataxia type 3 | |
| EP0963987A3 (en) | Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole) |